Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Parapsoriasis 1Lymphoma, Follicular 1Dermatitis, Contact 1Acne Vulgaris 1

Interventions

Rituximab 301Cyclophosphamide 241Peripheral Blood Stem Cell Transplantation 115fludarabine phosphate 111Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 81Vincristine 79Prednisone 79Mycophenolic Acid 67Doxorubicin 62Whole-Body Irradiation 59Cyclosporine 59Bendamustine Hydrochloride 59Melphalan 57Tacrolimus 54Busulfan 52obinutuzumab 50fludarabine 50Cytarabine 49Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 33ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Gels × Lymphoid × Clear all
NCT02796066 2017-04-26

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

Thesan Pharmaceuticals, Inc.

Phase 2 Withdrawn
Lymphoid

Acne Vulgaris, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡